Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02209519 · ClinicalTrials.gov registry record · Phase 3

Randomized Controlled Trial of Treatment of Male Partners of Women With BV

A Phase 3 study, sponsored by University of Alabama at Birmingham.

Completed
Registry status
Phase 3
Development phase
214
Enrollment target

NCT02209519: Completed Phase 3 study, sponsored by University of Alabama at Birmingham.

NCT02209519 is a Phase 3 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 214 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02209519, a Phase 3 study, has completed, sponsored by University of Alabama at Birmingham.

COMPLETED
Registry status
Phase 3
Development phase
214 participants
Enrollment target

Study Summary

Male partners of womoen with recurrent bacteria vaginosis are randomized to treatment with metronidazole or placebo to compare the rates of recurrent BV in the women

Primary Outcome

the female partners will be assessed for recurrence/persistence of BV. tRecurrence/persistence is measured by - Positive 3 - 4 Amsel criteria (vaginal pH \> 4.7, clue cells, positive whiff test, homogenous discharge); Nugent score \>3 No Recurrence/Persistence is measured by: \- Presence of 0 -2 Amsel criteria; Nugent score 0-3.

Interventions

  • DRUG Metronidazole (male partner)
  • OTHER Placeob (male partner)

Trial Details

FieldValue
Enrollment Target 214 participants
Start Date 2015-02
Est. Completion 2019-03
Phase Phase 3
University of Alabama at Birmingham

1,160 total trials

What the finished NCT02209519 record still lists

NCT02209519 is an interventional study that assigns participants to a tested intervention. The registered 214 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower).

The record links to 0 conditions, and to 2 interventions - of which Metronidazole (male partner) is the first listed.

NCT02209519 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02209519 about?

NCT02209519 is a clinical study titled "Randomized Controlled Trial of Treatment of Male Partners of Women With BV". Male partners of womoen with recurrent bacteria vaginosis are randomized to treatment with metronidazole or placebo to compare the rates of recurrent BV in the women

What is the current status of trial NCT02209519?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 214 participants. The study started on 2015-02. Estimated completion is 2019-03.

What interventions are being tested in trial NCT02209519?

The interventions under investigation include: Metronidazole (male partner) (DRUG), Placeob (male partner) (OTHER).

Who is sponsoring clinical trial NCT02209519?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02209519's enrollment target sits among peer trials

214 1335th of 2000 higher than 666 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04030507 · 214 participants · NA

    Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer

  • NCT04421248 · 214 participants · Phase 4

    Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder

  • NCT04667520 · 214 participants · NA

    Testing a Lifestyle Physical Activity Intervention for Women With Depression in Alcohol Treatment

  • NCT05418868 · 214 participants · Phase 1

    A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02209519, the US trial registry maintained by the National Library of Medicine. NCT02209519 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.